GSTM1 and ovarian cancer: These reports were validated in a study on a range of cancer victims receiving chemotherapy, in which grade 2+ (Hb < 10 g/dl) CIA incidence ranged from about 26% to 59% in colorectal and ovarian cancer, respectively, whereas severe anaemia (Hb <8 g/dl) was maximum in ovarian cancer (about 17%) and minimum in colorectal cancer (4%).106